According to relevant data, the market size of in vitro diagnostics in China in 2016 was only 45 billion yuan. With the improvement of patients' economic ability and access to medical services, as well as the impact of the epidemic, it is expected to maintain a healthy growth momentum in the next few years, with 15.4 % CAGR grows to RMB 219.8 billion in 2025 and RMB 351.5 billion in 2030.

Once upon a time, China's IVD market, like Indonesia's, was also firmly occupied by European and American companies. However, the following factors have changed the situation to a great extent, which is only my personal opinion:

one. The Chinese government vigorously promotes independent innovation in science and technology, and provides many preferential conditions for medical devices at the policy level.

two. The COVID-19 epidemic has brought development opportunities to many Chinese IVD companies. They have created huge profits by providing COVID-19 vaccines and testing reagents to the international market, and thus have the ability to invest in research and development.

three. At the government level, actively promote the reduction of personal medical consumption costs.

At present, China's in vitro diagnostic market only accounts for 5% of the global market, and the future development prospects are broad. With the further deepening of the reform of the pharmaceutical system, the implementation of relevant policies such as medical insurance cost control and hierarchical diagnosis and treatment will bring a major drive for domestic brands to replace imported brands.

The situation of IVD products in China is divided into the following three categories:

I. The strength is very strong, basically can be substituted, and exported to the international market:

1. Hematology Analyzer (representative manufacturers: Mindray and other manufacturers)

2. Urine analyzer and urine sediment analyzer (representative manufacturers: Dirui and other manufacturers)

3. Fecal analyzer (representative manufacturers: Sciendox and other manufacturers)

4. Biochemical analyzer (representative manufacturers: Mindray and other manufacturers)

5.Chemiluminescence analyzer CLIA (representative manufacturers: Mindray and other manufacturers)

6.Elisa Analyzer (representative manufacturers: Aikang and other manufacturers)

7. Fluorescence immunoassay analyzer (representative manufacturers: Wonderfo and other manufacturers)

8. Nucleic acid extraction instrument (representative manufacturers: Daan gene and other manufacturers)

9. PCR analyzer (representative manufacturers: Bioer and other manufacturers)

II. Partial import substitution:

1. Flow cytometer (representative manufacturers: Mindray and other manufacturers)

2. Blood coagulation analyzer (representative manufacturers: Mindray and other manufacturers)

3. Microbial ID & AST System (representative manufacturers: DL and other manufacturers)

4. Automatic blood culture instrument (representative manufacturers: DL and other manufacturers)

5. Mass spectrometer MALDI-TOF MS(representative manufacturers: Autobio and other manufacturers)

6. Blood grouping instrument (representative manufacturers: Autobio and other manufacturers)

7. Automatic in situ hybridization instrument（ISH）

III. Basically, foreign brands are the main ones, and domestic brands introduce technology for OEM production:

Gene sequencer (representative manufacturers: BGI and other manufacturers)

With the increase of research and development investment, the improvement of product technology level and the completion of mergers and acquisitions, the comprehensive competitiveness of Chinese IVD enterprises will be greatly improved, and the pattern of the in vitro diagnostic industry will change.

Visit https://www.fknmed.com/news/Human-Medial-News-9, we will share more industrial news with you.